GlassScriptPhysician profile
Brett J Van Briggle
NPI 1073961876
$1,469.97
in general payments reported to CMS, 2019-2025
26 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.07 · 2020: $37.01 · 2021: $177 · 2023: $153 · 2024: $265 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $224.64 | 2024-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $161.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $148.13 | 2021-2025 | |
| Pfizer INC. | $143.87 | 2023-2025 | |
| Bridgebio Pharma, INC. | $134.76 | 2025 | Attruby |
| Boston Scientific Corporation | $124.26 | 2023-2025 | Watchman Flx, Watchman Access System |
| Scpharmaceuticals INC. | $52.45 | 2024 | |
| Edwards Lifesciences Corporation | $51.59 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.51 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Kiniksa Pharmaceuticals International, Plc | $43.38 | 2024 | Arcalyst |
| Abiomed | $36.25 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.66 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $28.51 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $26.67 | 2025 | Winrevair |
| Alnylam Pharmaceuticals INC. | $23.66 | 2025 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.53 | 2025 | |
| United Therapeutics Corporation | $20.01 | 2025 | |
| Akcea Therapeutics, INC. | $19.80 | 2020 | |
| Baxter Healthcare | $18.77 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $18.37 | 2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $17.90 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.21 | 2020 | |
| Verona Pharma, INC. | $16.32 | 2025 | Ohtuvayre |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2023 | Inpefa |
| Electromed, INC. | $14.75 | 2025 | Smartvest |
| Abbott Laboratories | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Van Briggle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.